Master Alliance Provisions Guide (MAPGuide)

Search Results For:

  • Issue:
    • Term & termination | Effect of termination
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
PATH - Aridis, Rotavirus Vaccine Development Agreement
2007
Industry
Product development partnership
Vaccine
Early clinical (through Phase 2)
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Vaccine
Commercialization
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Vaccine
Commercialization
Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
2014
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
2020
Government
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Vaccine
Preclinical
Commercialization
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Vaccine
Commercialization
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Vaccine
Commercialization

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => Array
        (
            [issue] => Array
                (
                    [0] => effect-of-termination
                )

        )

    [filters] => Array
        (
            [provision] => Array
                (
                    [issue] => Array
                        (
                            [0] => effect-of-termination
                        )

                )

        )

    [child_filters] => Array
        (
        )

    [agreement_args] => 
    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [tax_query] => Array
                (
                    [0] => Array
                        (
                            [taxonomy] => issue
                            [field] => slug
                            [terms] => Array
                                (
                                    [0] => effect-of-termination
                                )

                        )

                )

        )

    [text_agreement_args] => 
    [text_provision_args] => 
    [agreement_ids] => Array
        (
        )

    [agreement_q_rslts] => 
    [provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => issue
                                    [field] => slug
                                    [terms] => Array
                                        (
                                            [0] => effect-of-termination
                                        )

                                )

                        )

                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [tax_query] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => issue
                                    [field] => slug
                                    [terms] => Array
                                        (
                                            [0] => effect-of-termination
                                        )

                                )

                        )

                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [s] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [taxonomy] => issue
                    [term] => effect-of-termination
                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                            [0] => Array
                                (
                                    [taxonomy] => issue
                                    [terms] => Array
                                        (
                                            [0] => effect-of-termination
                                        )

                                    [field] => slug
                                    [operator] => IN
                                    [include_children] => 1
                                )

                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                            [0] => wpry_term_relationships
                        )

                    [queried_terms] => Array
                        (
                            [issue] => Array
                                (
                                    [terms] => Array
                                        (
                                            [0] => effect-of-termination
                                        )

                                    [field] => slug
                                )

                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT   wpry_posts.* FROM wpry_posts  LEFT JOIN wpry_term_relationships ON (wpry_posts.ID = wpry_term_relationships.object_id) WHERE 1=1  AND ( 
  wpry_term_relationships.term_taxonomy_id IN (72)
) AND wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled') GROUP BY wpry_posts.ID ORDER BY wpry_posts.post_date DESC 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 3883
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:10:24
                            [post_date_gmt] => 2021-11-18 16:10:24
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-18 16:10:24
                            [post_modified_gmt] => 2021-11-18 16:10:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3883
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 3860
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:51:48
                            [post_date_gmt] => 2021-11-05 13:51:48
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-05 13:51:48
                            [post_modified_gmt] => 2021-11-05 13:51:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3860
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 3805
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:33:53
                            [post_date_gmt] => 2021-09-10 11:33:53
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-16 14:34:47
                            [post_modified_gmt] => 2021-09-16 14:34:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 3791
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:18:44
                            [post_date_gmt] => 2021-09-09 14:18:44
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-04 09:00:35
                            [post_modified_gmt] => 2021-11-04 09:00:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3791
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 3755
                            [post_author] => 5
                            [post_date] => 2021-08-25 07:55:51
                            [post_date_gmt] => 2021-08-25 07:55:51
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-08-25 07:57:09
                            [post_modified_gmt] => 2021-08-25 07:57:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3755
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 3417
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:04:34
                            [post_date_gmt] => 2021-06-30 19:04:34
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-01 15:12:39
                            [post_modified_gmt] => 2021-09-01 15:12:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3417
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 3356
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:53:23
                            [post_date_gmt] => 2021-06-30 13:53:23
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-02 14:37:29
                            [post_modified_gmt] => 2021-09-02 14:37:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3356
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 3344
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:02:36
                            [post_date_gmt] => 2021-06-30 13:02:36
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-22
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:03:45
                            [post_modified_gmt] => 2021-06-30 13:03:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3344
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 2962
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:50:18
                            [post_date_gmt] => 2021-05-28 18:50:18
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-23 12:38:17
                            [post_modified_gmt] => 2021-11-23 12:38:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2962
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 2909
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:13:58
                            [post_date_gmt] => 2021-05-19 15:13:58
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-08-22 10:55:43
                            [post_modified_gmt] => 2021-08-22 10:55:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 2744
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:12:35
                            [post_date_gmt] => 2021-03-30 15:12:35
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-08-12 13:48:08
                            [post_modified_gmt] => 2021-08-12 13:48:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 2553
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:47:42
                            [post_date_gmt] => 2021-03-12 13:47:42
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-10 11:20:09
                            [post_modified_gmt] => 2021-09-10 11:20:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2553
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 2482
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:09:37
                            [post_date_gmt] => 2021-01-25 13:09:37
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-09 14:17:13
                            [post_modified_gmt] => 2021-09-09 14:17:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 1287
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:05:30
                            [post_date_gmt] => 2020-05-22 23:05:30
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-23 13:03:53
                            [post_modified_gmt] => 2021-11-23 13:03:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1287
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 1284
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:58:55
                            [post_date_gmt] => 2020-05-22 22:58:55
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-08-20 12:10:28
                            [post_modified_gmt] => 2021-08-20 12:10:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1284
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 15
            [current_post] => -1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 3883
                    [post_author] => 5
                    [post_date] => 2021-11-18 16:10:24
                    [post_date_gmt] => 2021-11-18 16:10:24
                    [post_content] => 
                    [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-11-18 16:10:24
                    [post_modified_gmt] => 2021-11-18 16:10:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3883
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 15
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 1
            [is_search] => 
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => e2b2005be635677d3fef7f852c1717e1
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [stopwords:WP_Query:private] => 
            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [text_agreement_q_rslts] => 
    [text_provision_q_rslts] => 
    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 3883
                    [post_author] => 5
                    [post_date] => 2021-11-18 16:10:24
                    [post_date_gmt] => 2021-11-18 16:10:24
                    [post_content] => 
                    [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-11-18 16:10:24
                    [post_modified_gmt] => 2021-11-18 16:10:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3883
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 3860
                    [post_author] => 5
                    [post_date] => 2021-11-05 13:51:48
                    [post_date_gmt] => 2021-11-05 13:51:48
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-11-05 13:51:48
                    [post_modified_gmt] => 2021-11-05 13:51:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3860
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 3805
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:33:53
                    [post_date_gmt] => 2021-09-10 11:33:53
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-16 14:34:47
                    [post_modified_gmt] => 2021-09-16 14:34:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3805
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 3791
                    [post_author] => 5
                    [post_date] => 2021-09-09 14:18:44
                    [post_date_gmt] => 2021-09-09 14:18:44
                    [post_content] => 
                    [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-11-04 09:00:35
                    [post_modified_gmt] => 2021-11-04 09:00:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3791
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 3755
                    [post_author] => 5
                    [post_date] => 2021-08-25 07:55:51
                    [post_date_gmt] => 2021-08-25 07:55:51
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-08-25 07:57:09
                    [post_modified_gmt] => 2021-08-25 07:57:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3755
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 3417
                    [post_author] => 5
                    [post_date] => 2021-06-30 19:04:34
                    [post_date_gmt] => 2021-06-30 19:04:34
                    [post_content] => 
                    [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-01 15:12:39
                    [post_modified_gmt] => 2021-09-01 15:12:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3417
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 3356
                    [post_author] => 5
                    [post_date] => 2021-06-30 13:53:23
                    [post_date_gmt] => 2021-06-30 13:53:23
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-02 14:37:29
                    [post_modified_gmt] => 2021-09-02 14:37:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3356
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 3344
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:02:36
                    [post_date_gmt] => 2021-06-30 13:02:36
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-22
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:03:45
                    [post_modified_gmt] => 2021-06-30 13:03:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3344
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 2962
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:50:18
                    [post_date_gmt] => 2021-05-28 18:50:18
                    [post_content] => 
                    [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-11-23 12:38:17
                    [post_modified_gmt] => 2021-11-23 12:38:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2962
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 2909
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:13:58
                    [post_date_gmt] => 2021-05-19 15:13:58
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-08-22 10:55:43
                    [post_modified_gmt] => 2021-08-22 10:55:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 2744
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:12:35
                    [post_date_gmt] => 2021-03-30 15:12:35
                    [post_content] => 
                    [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-08-12 13:48:08
                    [post_modified_gmt] => 2021-08-12 13:48:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 2553
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:47:42
                    [post_date_gmt] => 2021-03-12 13:47:42
                    [post_content] => 
                    [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-10 11:20:09
                    [post_modified_gmt] => 2021-09-10 11:20:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2553
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 2482
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:09:37
                    [post_date_gmt] => 2021-01-25 13:09:37
                    [post_content] => 
                    [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-09 14:17:13
                    [post_modified_gmt] => 2021-09-09 14:17:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2482
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 1287
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:05:30
                    [post_date_gmt] => 2020-05-22 23:05:30
                    [post_content] => 
                    [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-11-23 13:03:53
                    [post_modified_gmt] => 2021-11-23 13:03:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1287
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 1284
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:58:55
                    [post_date_gmt] => 2020-05-22 22:58:55
                    [post_content] => 
                    [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-08-20 12:10:28
                    [post_modified_gmt] => 2021-08-20 12:10:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1284
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [invalid_get] => 
    [is_text_search] => 
    [has_agreement_filters] => 
    [has_any_agreement_filter] => Array
        (
        )

    [found_agreements] => 
    [has_provision_filters] => 1
    [found_provisions] => 1
    [lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
    [lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
    [lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
    [lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
    [lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
    [lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
    [lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
    [issues_by_id:GHIAA2019\MapguideSearch:private] => Array
        (
            [101] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [100] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [66] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [53] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [84] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 35
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [59] => WP_Term Object
                (
                    [term_id] => 59
                    [name] => Conflict of Interest
                    [slug] => conflict-of-interest
                    [term_group] => 0
                    [term_taxonomy_id] => 59
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 2
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [51] => WP_Term Object
                (
                    [term_id] => 51
                    [name] => Consortium structure & management
                    [slug] => consortium-structure
                    [term_group] => 0
                    [term_taxonomy_id] => 51
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 9
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [82] => WP_Term Object
                (
                    [term_id] => 82
                    [name] => Data management
                    [slug] => data-management
                    [term_group] => 0
                    [term_taxonomy_id] => 82
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 9
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [267] => WP_Term Object
                (
                    [term_id] => 267
                    [name] => Dispute resolution
                    [slug] => dispute-resolution
                    [term_group] => 0
                    [term_taxonomy_id] => 267
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [290] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Dissemination of Results
                    [slug] => dissemination-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 19
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [271] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [72] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effect of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 15
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [281] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 18
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [46] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable Access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [92] => WP_Term Object
                (
                    [term_id] => 92
                    [name] => Exploitation of results
                    [slug] => exploitation-results
                    [term_group] => 0
                    [term_taxonomy_id] => 92
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 27
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [80] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 22
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [49] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Information & materials sharing
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [257] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [109] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [48] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual Property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [50] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [79] => WP_Term Object
                (
                    [term_id] => 79
                    [name] => Limitation of liability
                    [slug] => limitation-of-liability
                    [term_group] => 0
                    [term_taxonomy_id] => 79
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 28
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [85] => WP_Term Object
                (
                    [term_id] => 85
                    [name] => Material transfer
                    [slug] => material-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 85
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 7
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [54] => WP_Term Object
                (
                    [term_id] => 54
                    [name] => Other
                    [slug] => other
                    [term_group] => 0
                    [term_taxonomy_id] => 54
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [87] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of background IP
                    [slug] => ownership-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 17
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [89] => WP_Term Object
                (
                    [term_id] => 89
                    [name] => Ownership of results
                    [slug] => ownership-results
                    [term_group] => 0
                    [term_taxonomy_id] => 89
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 34
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [70] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment Structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 22
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [102] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [268] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [90] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 26
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [56] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 18
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [279] => WP_Term Object
                (
                    [term_id] => 279
                    [name] => Reporting Requirements
                    [slug] => reporting-requirements
                    [term_group] => 0
                    [term_taxonomy_id] => 279
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 51
                    [count] => 3
                    [filter] => raw
                    [parent_name] => Consortium structure & management
                    [parent_slug] => consortium-structure
                )

            [81] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & Warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 21
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [278] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Roles & Responsibilities
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 51
                    [count] => 7
                    [filter] => raw
                    [parent_name] => Consortium structure & management
                    [parent_slug] => consortium-structure
                )

            [86] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 12
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [52] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 1
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [76] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 22
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [74] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 21
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [282] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [88] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => Use of background IP
                    [slug] => use-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 25
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

        )

    [issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
        (
            [equitable-access] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [pricing] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [benefit-revenue-sharing] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [business-model] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [confidentiality] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 35
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [conflict-of-interest] => WP_Term Object
                (
                    [term_id] => 59
                    [name] => Conflict of Interest
                    [slug] => conflict-of-interest
                    [term_group] => 0
                    [term_taxonomy_id] => 59
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 2
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [consortium-structure] => WP_Term Object
                (
                    [term_id] => 51
                    [name] => Consortium structure & management
                    [slug] => consortium-structure
                    [term_group] => 0
                    [term_taxonomy_id] => 51
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 9
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [data-management] => WP_Term Object
                (
                    [term_id] => 82
                    [name] => Data management
                    [slug] => data-management
                    [term_group] => 0
                    [term_taxonomy_id] => 82
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 9
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [dispute-resolution] => WP_Term Object
                (
                    [term_id] => 267
                    [name] => Dispute resolution
                    [slug] => dispute-resolution
                    [term_group] => 0
                    [term_taxonomy_id] => 267
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [dissemination-of-results] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Dissemination of Results
                    [slug] => dissemination-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 19
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [donation] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [effect-of-termination] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effect of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 15
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [ensuring-continuity] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 18
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [access-to-medicines] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable Access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [exploitation-results] => WP_Term Object
                (
                    [term_id] => 92
                    [name] => Exploitation of results
                    [slug] => exploitation-results
                    [term_group] => 0
                    [term_taxonomy_id] => 92
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 27
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [indemnity] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 22
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [information-sharing] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Information & materials sharing
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [information-sharing-information-sharing] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [insurance] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [ip-ownership] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual Property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [liability] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [limitation-of-liability] => WP_Term Object
                (
                    [term_id] => 79
                    [name] => Limitation of liability
                    [slug] => limitation-of-liability
                    [term_group] => 0
                    [term_taxonomy_id] => 79
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 28
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [material-transfer] => WP_Term Object
                (
                    [term_id] => 85
                    [name] => Material transfer
                    [slug] => material-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 85
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 7
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [other] => WP_Term Object
                (
                    [term_id] => 54
                    [name] => Other
                    [slug] => other
                    [term_group] => 0
                    [term_taxonomy_id] => 54
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [ownership-background-ip] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of background IP
                    [slug] => ownership-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 17
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [ownership-results] => WP_Term Object
                (
                    [term_id] => 89
                    [name] => Ownership of results
                    [slug] => ownership-results
                    [term_group] => 0
                    [term_taxonomy_id] => 89
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 34
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [royalties-and-payments] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment Structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 22
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [outbreak-preparedness] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [supply-purchase-of-products] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [protection-results] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 26
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

            [regulatory-strategy] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 18
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [reporting-requirements] => WP_Term Object
                (
                    [term_id] => 279
                    [name] => Reporting Requirements
                    [slug] => reporting-requirements
                    [term_group] => 0
                    [term_taxonomy_id] => 279
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 51
                    [count] => 3
                    [filter] => raw
                    [parent_name] => Consortium structure & management
                    [parent_slug] => consortium-structure
                )

            [warranties] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & Warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 21
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [roles-responsibilities] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Roles & Responsibilities
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 51
                    [count] => 7
                    [filter] => raw
                    [parent_name] => Consortium structure & management
                    [parent_slug] => consortium-structure
                )

            [technology-transfer] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 12
                    [filter] => raw
                    [parent_name] => Information & materials sharing
                    [parent_slug] => information-sharing
                )

            [term-and-termination] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 1
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [term-of-agreement] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 22
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [termination-and-withdrawal] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 21
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [territory-access-commitments] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Equitable Access
                    [parent_slug] => access-to-medicines
                )

            [use-background-ip] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => Use of background IP
                    [slug] => use-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 25
                    [filter] => raw
                    [parent_name] => Intellectual Property
                    [parent_slug] => ip-ownership
                )

        )

    [filter_issues:GHIAA2019\MapguideSearch:private] => Array
        (
            [0] => effect-of-termination
        )

)